riximyo
sandoz do brasil indÚstria farmacÊutica ltda - rituximabe - antineoplasico
vivaxxia
libbs farmacÊutica ltda - rituximabe - antineoplasico
becenun
biolab sanus farmacÊutica ltda - nitrosureias alquilantes
farmorubicina
laboratÓrios pfizer ltda - antibioticos antineoplasicos
ruxience
pfizer brasil ltda - rituximabe - antineoplasicos citotoxicos
nibisnu
dr. reddys farmacÊutica do brasil ltda - carmustina - nitrosureias alquilantes
akynzeo
united medical ltda - netupitanto, cloridrato de palonosetrona - antiemÉticos e antinauseantes
noripurum
blanver farmoquimica e farmacÊutica s.a. - ferripolimaltose - antianemicos simples
noripurum fólico
blanver farmoquimica e farmacÊutica s.a. - ferripolimaltose, Ácido fÓlico - antianemicos a base de ferro - associacoes medicamentosas
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agentes antineoplásicos - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.